Figure 5.

Changes in eosinophil counts of patients who underwent post-dupilumab therapy. PBE changes from the start of dupilumab treatment to 3 (A) and 6 months (B) are shown. The arrows indicate changes in PBE in patients who later developed EGPA. A patient diagnosed with EGPA at 3.6 months is shown in (A). This patient was not included in the observation of PBE changes at 6 months (B) because dupilumab was discontinued at the diagnosis of EGPA. Black dotted line: patients without biologics premedication, red line: patients premedicated with anti-IL-5/IL-5R, blue dotted line: patients premedicated with omalizumab. Green line: PBE counts 1500 cells/μL.